LightInTheBox Reveals Q1 Numbers
LightInTheBox Holding Co., Ltd. (NYSE: LITB) came out with financial figures to begin Tuesday. The company, a global specialty retailer focusing on proprietary apparel brands and design-driven collections tailored to evolving consumer preferences, today announced its unaudited financial results for the first quarter ended March 31, 2025. The company's strategic shift toward high-margin proprietary brands delivered sustained profitability despite a challenging e-commerce landscape.First-Quarter total revenues were $47.0 million, a 34% decrease year over year, reflecting a deliberate focus on margin preservation over market share in a competitive market.Gross Profit was $30.6 million, compared with $41.4 million in the same quarter last year.Gross Margin improved to 65.2% from 58.2% in the same quarter last year, driven by the Company's higher-margin proprietary product lines.Operating Expenses declined by 33% year over year to $30.5 million, mainly attributable to reduced revenue along with effective cost management and operational efficiency enhancements.Net Income reached $0.1 million, compared with a net loss of $3.8 million in the same quarter last year, marking sustained profitability amidst industry challenges.Adjusted EBITDA was an income of $0.6 million, compared with a loss of $3.1 million in the same quarter last year.CEO Jian He commented, "In 2024, we transformed LightInTheBox into a brand-focused apparel company, prioritizing profitability and launching proprietary brands like Ador and other apparel lines.” LITB shares closed Monday at $1.32.
Recent Posts

Romanian Inflation Ends Tumultuous Year in Politics Close to 10%

UK Boosts Support For Offshore Wind in Bumper Auction

Ireland Is Trying to Get Back on the Data Center Bandwagon

Notice Concerning Change of Representative Executive Officer

Polish Recycler Bets Millions on Europe’s Critical Metals Push

Blistering Metals Rally Sends Silver, Tin and Copper to Records

Wellington Management Appoints Alex Behm to Strengthen Secondaries Capabilities

TCS and AMD Announce Strategic Collaboration to Drive AI Adoption at Scale

New data reinforces Ipsen’s commitment to bringing solutions and addressing care gaps in neurological diseases at TOXINS

TOXINS 2026: Clinical Updates on Galderma’s Leading Neuromodulator Portfolio Further Reinforce Its Leadership in Injectable Aesthetics


